Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Molecular markers guiding treatment approaches in bladder cancer

Daniel Petrylak • 4 Jun 2022
ASCO 2022
Bladder Cancer Genitourinary Cancer Enfortumab vedotin Erdafitinib Sacituzumab govitecan

Daniel Petrylak, MD, Yale Cancer Center, New Haven, CT, reflects on key areas of unmet need in bladder cancer research, including the importance of molecular markers to guide personalized treatment approaches. Novel targeted therapies such as enfortumab vedotin, erdafitinib and sacitizumab govetican are being moved to earlier lines of treatment, highlighting the importance of patient stratification. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Daniel Petrylak

0:43
Current developments in FGFR inhibitors for urothelial cancer
Daniel Petrylak • 3 Jun 2023
1:59
How can we best sequence novel treatments in urothelial cancer?
Daniel Petrylak • 3 Jun 2023
0:24
HER2-targeting ADCs for urothelial carcinoma
Daniel Petrylak • 3 Jun 2023
1:04
THOR: erdafitinib in advanced or metastatic urothelial cancer and FGFR alterations
Daniel Petrylak • 3 Jun 2023

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals